👉CYBN is TODAY’S #1 ALERT 👈

Hey Folks, Jeff Bishop here,

It’s no secret that the Trump Administration — especially Health Secretary RFK Jr. — is open to psychedelic therapies for treating things like depression.

“This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months,” RFK Jr. told members of Congress earlier this year.

My “tactical trade” idea today is a very prominent company in this space.

💥I want you to pull up Cybin (CYBN) right now and take a very close look at it.

You’ll see the stock had a very nice recovery from its April “Liberation Day” dip, but starting in July, it has trended back down.

What I’m especially interested in is its price action in September…

You can see that it started the month with a nice bounce from the $6.00 level before dropping back down to that level around September 11.

Since that time, it has hovered right at that support, and momentum indicators like the Stochastic and RSI suggest the stock is possibly oversold.

If buyers step in at this level, a run toward resistance in the $7–8 range could follow, so make sure you’re watching it closely.

On the other hand, if it drops below its current support level, it might make sense to wait for a better entry point.

With positive movement yesterday during the session and after hours, I’m watching CYBN today to see if we get a bounce from here.

👉  CYBN is TODAY’S #1 ALERT 👈

I think you’ll really like learning what CYBN does.

It is not your typical small stock.

CYBN is a leader in developing psychedelic-based therapies for mental illnesses, including major depressive disorder (MDD), generalized anxiety disorder (GAD), and alcohol use disorder (AUD).

CYBN is a clinical-stage biopharmaceutical company that takes its name from psilocybin — the active ingredient in “magic mushrooms.” 🍄

The company has been featured in the likes of Time, Forbes, Business Insider, and many other prominent media.

And if there was any doubt about CYBN’s prominent standing in this space, the fact that the company received a Breakthrough Therapy Designation (BTD) for its novel CYB003 molecule should clear that up.

According to the FDA, which grants that designation, it is “designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy.”

It not only grants the recipient all the benefits of “Fast Track,” the company said it also includes “more intensive FDA guidance and discussion of the CYB003 development program, including planned clinical trials and plans for expediting the manufacturing development strategy.”

“CYB003 is eligible for Priority Review and Accelerated Approval,” the company added.

CYBN also said this is the “first known BTD granted by the FDA for an adjunctive psychedelic-based therapy for the treatment of Major Depressive Disorder.”

This landmark achievement comes after the company completed its Phase II clinical trial of CYB003 — a proprietary molecule derived from psilocybin — for MDD.

The trial’s results were extraordinary…

Researchers found that, 12 months after dosing, “100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003.” [emphasis added]

This chart plots the results in terms of scores on the Montgomery-Asberg Depression Rating Scale (“MADRS”). 

As you can see, even at D364 (day 364, or 12 months after dosing), recipients had dramatic reductions in depression scores. (A score of 0–6 is considered normal; 7–19 is mild depression).

Better yet, when compared with existing MDD treatments, including the popular SSRIs, CYB003 trounced the competition after just a single dose:

I didn’t realize this, but more than 43 million Americans take antidepressants, and more than 70% of them are treated with SSRIs.

If these results continue playing out, this could be a very big deal.

CYB003 is now in Phase 3 trials for treating major depression, with patient dosing already underway in the U.S. and enrollment starting soon across Europe and the UK, and the big readouts are expected in 2026.

On top of CYB003, the company is also developing a DMT–derived compound (CYB004) for the treatment of generalized anxiety disorder.

On September 8, the company announced it had completed enrollment for a Phase 2 study of the treatment, and it reaffirmed that “top-line data guidance expected in the first quarter of 2026.”

I’m very impressed with CYBN’s management team, which has brought dozens of drugs to market, including widely used drugs such as Allegra, Lexapro, Anzemet, Latuda, and Vaniqa. The scientific team has more than 300 combined peer-reviewed publications between them.

CYBN is currently covered by half a dozen analysts, and their price targets — all recently reiterated — are nothing short of astonishing:

Folks, the average price target is 1,300% higher than its current price!

As you do your own research on CYBN, be sure to check out the company website and this investor presentation released this month.

And of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well, so you are aware of additional risks and considerations. Always have a well-thought-out game plan that considers your personal risk tolerance.

To Your Success,

Jeff Bishop

*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Sica Media for advertising Cybin Inc for a one day marketing program starting on September 23, 2025. Previously, we were paid twenty thousand dollars from Sideways Frequency, who was compensated by a third party not affiliated with the Company for advertising Cybin Inc for a one-day marketing program commencing on March 15, 2024. It might seem obvious, but while our client claims not to own any shares in Cybin Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Cybin Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.